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Abstract
Background: Heart rate variability (HRV) decreases in Parkinson’s disease (PD) and it can be considered a marker for
cardiovascular dysautonomia. The purpose of this pilot study is to evaluate long-term time-domain analysis of HRV
of PD patients and compare the results with those of matched healthy individuals.
Methods: Idiopathic PD patients without comorbidity impairing HRV, and age-matched healthy individuals were
recruited in a pilot study. A long-term time domain analysis of HRV using 24-h ambulatory ECG was performed.
Results: Overall, 18 PD patients fulfilling inclusion criteria completed the evaluation (mean age was 55.6 ± 8.8,
disease duration: 5.0 ± 4.7). Mean SCOPA-AUT score was 10.1 ± 7.3. Patients were on Hoehn & Yahr stage 1–2 and
mean Levodopa Equivalent Dose (LED) was 311 ± 239.9. Mean of the 5-min standard deviation (SD) of R-R intervals
distribution (SDNN) for all 5 min segments of the entire recording (ISDNN) was significantly lower in patients
compared to controls. ISDNN was significantly different between Parkinson’s disease patients and healthy controls.
Conclusions: In our population characterized by mild to moderate disease severity, time-domain assessment of
HRV seemed to be a potential tool to characterize cardiovascular dysautonomia. Decrease of ISDNN in PD may
reflect an autonomic derangement extending all day and night long.
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Background
Heart rate variability (HRV) is decreased in Parkinson’s
disease (PD) and it could occur early [1] in the course of
the disease. HRV can be considered a marker for cardio-
vascular sympathovagal balance [2]. HRV is a non-
invasive widespread tool for studying heart rate regulation
in relation to autonomic system. HRV might be evaluated
by a short term (usually 5min) ECG recording obtained
under controlled standardized conditions and long term
analysis [3]. Typically, higher values of HRV reflect better
health and studies using HRV evaluation have reported
that it declines in patients with PD compared to healthy
matched controls, in short and long recordings [4, 5].
Short-time spectral analysis is often used in PD patients
because it is a fast, low-cost and patient-independent
measure, with good intra-individual reproducibility for
HRV [3–6]. However, it has been observed that patients
with normal responses to short-time spectral analysis tests
could suffer from impaired HRV evaluated by a long-term
time analysis [3]. Time domain analysis by a 24-h ECG re-
cording could be a valid tool for characterizing cardiac
autonomic state in PD and 24-h HRV indices appear to be
stable and free of placebo effect [7].
The main aim of our study was to evaluate whether a
difference between PD patients without comorbidities
impairing long term time-domain HRV and healthy
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controls exists. Whether a difference was observed, we
determined the characteristics of the disease associated
with HRV impairment. A time-domain assessment of
HRV was performed using a long term recording.
Methods
Characteristics of the population
This was an observational, cross-sectional, comparative
pilot study carried-out in an ambulatory setting. Non-
demented PD patients were consecutively recruited from
our department. Patients with suspected atypical or sec-
ondary parkinsonism were excluded, as well as those
with comorbidities known to influence HRV (hyperten-
sion, diabetes, heart diseases, heart failure, myocardial
infarction), or those patients taking drugs that are
known to reduce HRV (antidepressants, selegeline, anti-
cholinergic, mineral corticoids, beta blockers, calcium
blockers, antiarrhythmics). Similar exclusion criteria
were used for healthy controls (individuals non affected
by Parkinson’s disease or other neurological disorders),
who were matched 1:1 for sex and age to PD patients.
All the participants gave their informed consent to par-
ticipate in the study. The study was approved by the
local ethics committee (Palermo1 v.n.5/13.05.2015) and
conducted according to the principles of the Declaration
of Helsinki.
During the study period, 127 patients (males, 55%)
were evaluated. Overall, 104 patients were excluded be-
cause they did not meet the inclusion criteria (22 de-
mented, 82 for other comorbidities or taking drugs
affecting HRV). Five of the final 23 patients invited, re-
fused to participate in the study.
Clinical and ECG evaluation
Each patient underwent an extensive evaluation includ-
ing Hoehn & Yahr stage (H&Y) [8], Unified Parkinson’s
Disease Rating Scale (UPDRS) [9], and Scale for
Outcomes in PD for autonomic symptoms (SCOPA-
AUT) [10]. Medications and comorbidities were re-
corded, using the Cumulative Illness Rating Scale (CIRS)
[11]. Levodopa Equivalent Daily Dose (LED) [12] was
also calculated. A long term time domain analysis of
heart rate variability (HRV) using 24-h 12-lead ECG re-
cording (at least 18-h ECG), encompassing morning and
night hours was performed and evaluated according to
the NASPE/ESC Task Force [7] in PD patients and age-
matched healthy individuals. Both groups were asked to
perform normal daily activity excluding intense physical
activity. All time domain parameters analysed have been
summarized in Table 1 and calculated using “cardioscan
II” software (version 11.4.0054a).
Statistics
Results are expressed as mean ± SD, with p ≤ 0.05 con-
sidered significant. Analysis of normality was performed
with the Shapiro-Wilk W test (α: 0,05). Differences be-
tween cases and controls of HRV time domain parame-
ters were calculated by t-test analysis. When a variable
of the HRV time domain analysis was found significantly
different between cases and controls, its association with
explored PD variables was evaluated by Pearson correl-
ation. Furthermore, linear regression analysis investi-
gated for correlations between patient characteristics:
age, LED, HY, LEVODOPA, SCOPA-AUT (independent
variables) and HRV time domain parameters (dependent
variable) in simple and multiple regression models. B co-
efficients (B) and their 95% confidence intervals (CIs)
were also calculated. The post-hoc statistical power and
the effect sizes on the basis of standardized mean differ-
ences (Cohen’s d) were performed too by Clin.Calc.com
(https://ckinical.com/stat/Power-aspx accessed on 01/
12/2019) and G*Power 3.1.9.3 software to compute stat-
istical power in sample size of our pilot study.
Table 1 HRV Time domain parameters evaluated in PD patients and controls
Variables Description (unit)
SDNN 24 Standard deviation (SD) of all NN intervals (ms)
SDNN D
SDNN N
pnn50 24 Percentage of successive RR intervals that differ by more than 50 ms (%)
pnn50 D
pnn50 N
rMSS 24 Root mean square of successive RR interval differences (ms)
rMSS D
rMSS N
SDANN Standard deviation of the average NN intervals for each 5 min segment of a 24 h HRV recording (ms)
ISDNN Mean of the Standard deviation of all NN intervals for all 5 min segments of the entire recording (ms)
PD Parkinson’s disease, D day, N: night
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Results
Overall, eighteen PD patients (9 males) with a mean dis-
ease duration of 50 ± 4.7 years were enrolled in this
study. No significant difference of age at HRV evaluation
was observed between PD patients (mean age 55.6 ± 8.8
years), and controls (mean age 56.0 ± 9.4 years) (p = 0.8).
PD patients had a mean SCOPA-AUT scale score of
10.1 ± 7.3. Patients with PD were characterized by mild
to moderate disease severity (HY stage 1–2) and mean
LED was 311 ± 239.9. Only SDNN index (ISDNN),
evaluating mean of the standard deviations of all NN in-
tervals for all 5 min segments of the entire recording,
was significantly different between PD patients (42.9 ±
14.2 ms) and healthy controls (53.4 ± 10.1 ms) (p =
0.01)(see Table 2). We plotted ISDNN values for PD pa-
tients and controls (see Fig. 1). Statistical power was cal-
culated (power 72. 5%, α:0.05), whereas, observed
Cohen’d was 0. 85.
ISDNN significantly correlated with age (r − 0.69, p =
0.02), LED (r − 0.60, p = 0.01), levodopa dosage (r − 0.57,
p = 0.02) and SCOPA-AUT scale scores (r − 0.47, p =
0.05). At linear regression analysis in simple regression
model, a statistically significant relationship between
age, levodopa dosage, HY and LED and ISDNN (see
Fig. 2) was observed, but not confirmed in multiple re-
gression model.
Discussion
In our study, recruiting only non-demented PD patients,
with mild to moderate disease severity and no other
conditions (comorbidities or treatments) known to affect
HRV, ISDNN was significantly different between Parkin-
son’s disease patients and healthy controls. ISDNN
seems to correlate with age, severity of disease stage,
LED and levodopa dosages. Taking into account the task
force on the HRV, SDNN, reflecting over heart variabil-
ity, is not a well-defined statistical variable due to its de-
pendence on ECG time recording, while ISDNN,
evaluating too over heart variability, is a more standard-
ized variable [7].
ISDNN most closely correlates with age, declining
with aging; gender also influences HRV (women had
lower values); however in our study we enrolled PD pa-
tients and healthy controls matched for age and sex [13].
In a recent study, including 1.741 PD patients (ECG
recording has been available for 653 PD patients), no as-
sociation was reported between HRV (SDNN and rMSS)
and PD severity or its progression [14], although routine
ECG data (standard 10-s 12-lead ECG) was used to per-
form HRV; standard ECG recording is considered inad-
equate for measuring HRV. According to the task force
on the HRV, short-term 5-min recordings and nominal
24-h long-term recordings seem to be appropriate op-
tions. Moreover, patients with significant comorbidities
or those taking drugs impairing HRV were not excluded.
ISDNN, the mean of the 5-min standard deviation of the
NN interval calculated over 24 h, which measures the
variability due to cycles shorter than 5min, requires a
24-h ECG recording. Both cardiac sympathetic and para-
sympathetic dysfunctions are commonly reported in PD
[15] ISDNN primarily reflects autonomic influence on
heart rate variability [16]. Decrease of ISDNN, reflecting
over variability of HRV, may be demonstrated in PD by
a sympathovagal balance impairment. A body of evi-
dence has challenged the traditional view of PD as a
motor disorder, in favour of the idea of PD being a more
complex disorder, including non-motor symptoms [17].
Among non-motor symptoms, autonomic dysfunction is
frequent in PD patients [18, 19] with cardiovascular
autonomic dysfunction occurring early in the course of
the disease [20]. ISDNN, evaluating HRV in 24 h, implies
a more complex derangement extending all day and all
night and it could reflect an impairment of diurnal-
temporal component; suggesting an imbalance of circa-
dian system as observed for other non-motor symptoms
in PD. The balance between sympathetic and parasym-
pathetic varies in synchrony with the circadian system
[21]. Circadian dysfunction could be part of the new
view of PD highlighting the role of non-motor symptoms
and its temporal pattern. Our pilot study was character-
ized by strengths and limitations. The major strength of
our study was the inclusion of individuals (patients and
healthy controls) without comorbidities or taking drugs
known to affect HRV. The observed difference in HRV
between the two groups was therefore hypothetically al-
most exclusively due to the presence of PD. Other
strengths of our study were the strict matching for age
and sex between cases and controls, as well as the use of
Table 2 HRV parameters (means ± SD) in PD patients and
controls
Variables PD patients (18) Controls (18) p
SEX(men%) 9(50) 9(50)
AGE(years) 55.6 ± 8.8 55.6 ± 8.8 0.8
SDNN 24(ms) 122.6 ± 38.3 136.0 ± 21.4 0.2
SDNN D(ms) 84.3 ± 27.9 96.2 ± 36.5 0.3
SDNN N(ms) 112.6 ± 40.9 119 ± 31.3 0.6
pnn50 24(%) 4.5 ± 4.1 5.3 ± 5.3 0.6
pnn50 D(%) 2.5 ± 2.3 3.8 ± 4.8 0.3
pnn50 N(%) 9.3 ± 9.4 8.4 ± 7.6 0.8
rMSS 24(ms) 24.9 ± 7 25.9 ± 7.7 0.7
rMSS D(ms) 20.8 ± 5.5 23.4 ± 8.9 0.3
rMSS N (ms) 31.1 ± 11.9 29.6 ± 9.5 0.7
SDANN(ms) 118.1 ± 38.8 124.7 ± 21.2 0.5
ISDNN(ms) 42.9 ± 14.2 53.4 ± 10.1 0.01
PD Parkinson’s disease; D day; N night
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a validated scale, the SCOPA-AUT, in order to detect
the presence of autonomic dysfunction. The main limita-
tion of our pilot study was the small sample size, attrib-
utable to the decision to adopt rigid exclusion criteria
including concomitant medical issues and the use of
some drugs. This led to the elimination of nearly 65% of
the patients. It is presumable that, in an ambulatory set-
ting, autonomic evaluation would be in the near future
considered together with motor and other non-motor
examination. The evaluation should include a question-
naire such as the SCOPA-AUT scale, and tools such as
the long-term time-domain assessment of HRV; as low-
cost and fast evaluations have to be fostered, our find-
ings suggest that, in an ambulatory setting, the use of
HRV analyses could be considered as part of an instru-
mental evaluation for the detection of autonomic dys-
function. This is in fact a promising, simple, non-
invasive and low-cost test for cardiovascular autonomic
symptoms in PD patients.
Conclusions
Autonomic symptoms are common but often
unrecognized in patients with Parkinson’s disease. In
our population characterized by mild to moderate
disease severity, time-domain assessment of HRV
seemed to be a potential tool for characterizing car-
diovascular dysautonomia. In our pilot study, ISDNN
was significantly different between PD patients and
matched healthy controls. In an ambulatory setting,
according to our findings, the use of HRV analysis
could be considered as part of an instrumental
evaluation for cardiovascular autonomic symptoms in
PD patients.
Fig. 1 ISDNN mean and standard deviations in PD patients and controls
Fig. 2 correlation by linear regression between ISDNN and clinical PD variables (AGE, Levodopa dosage, HY, LED)
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